← All trials
NCT04983030
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2021
- Primary completion
- Mar 1, 2024
- Completion date
- Mar 1, 2024
- First posted
- Jul 30, 2021
- Last posted
- Jul 30, 2021
- Enrollment
- 36
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harvard UniversityLead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Harvard UniversityCollaborator
- Harvard UniversityOverall official - principal investigator
- Harvard UniversitySponsor investigator
- Orlando Immunology CenterCollaborator
- Janssen Pharmaceutica NVCollaborator
- University of Texas at HoustonCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.